Literature DB >> 2933381

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

J Boerema, B Boll, H Muytjens, J Branolte.   

Abstract

In an open study 28 patients were treated for complicated UTI with ciprofloxacin 250 mg every 12 h for 10 days. The most frequently isolated species were Escherichia coli and Klebsiella pneumoniae. All pathogens were sensitive to ciprofloxacin in vitro. Twenty-three of the 28 patients (82%) were free of infection 5-9 days after therapy. A persistent infection was noted in two patients (7%) and a reinfection in three patients (11%). Four to six weeks after the end of therapy, 18 patients (64%) were still totally free of infection. Clinical resolution of symptoms and signs occurred in 27 patients (96%). Adverse reactions were spontaneously reported by four of the 28 patients (14%) and by 11 (39%) after detailed inquiry. Most side effects were of gastrointestinal or neurological nature. This small open study supports the view, that ciprofloxacin may be useful in the treatment of complicated UTI.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933381     DOI: 10.1093/jac/16.2.211

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Rapid improvement of hepatic encephalopathy associated with oral ciprofloxacin treatment.

Authors:  S Esposito; D Galante; O Laghezza; D Barba; G B Gaeta
Journal:  Infection       Date:  1987       Impact factor: 3.553

2.  Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections.

Authors:  J M Allais; L C Preheim; T A Cuevas; J S Roccaforte; M A Mellencamp; M J Bittner
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 3.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

4.  Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.

Authors:  G D Fang; C Brennen; M Wagener; D Swanson; M Hilf; L Zadecky; J DeVine; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 5.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

6.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

8.  New 4-quinolones in the treatment of urinary tract infections.

Authors:  J B Boerema
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Tissue distribution of ciprofloxacin following oral and intravenous administration.

Authors:  A Dalhoff; H U Eickenberg
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.